Get the Stockscreener App
68.57
1.76%
-1.23
Soleno Therapeutics Inc stock is traded at $68.57, with a volume of 1.15M.
It is down -1.76% in the last 24 hours and down -20.29% over the past month.
Soleno Therapeutics Inc is a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases. Its product candidate DCCR (Diazoxide Choline) Extended-Release tablets, is a proprietary extended-release formulation of a crystalline salt of diazoxide. DCCR has demonstrated the ability to activate the KATP channel in the brain, pancreas, and fat tissue.
See More
Previous Close:
$69.80
Open:
$70.23
24h Volume:
1.15M
Relative Volume:
0.92
Market Cap:
$3.64B
Revenue:
-
Net Income/Loss:
$-38.99M
P/E Ratio:
-22.88
EPS:
-2.9966
Net Cash Flow:
$-24.94M
1W Performance:
-4.27%
1M Performance:
-20.29%
6M Performance:
+48.65%
1Y Performance:
+41.09%
1-Day Range:
$68.02
$70.29
1-Week Range:
$66.72
$71.98
52-Week Range:
$41.50
$90.32
Soleno Therapeutics Inc Stock (SLNO) Company Profile
Name
Soleno Therapeutics Inc
Sector
Industry
Phone
650-213-8444
Address
100 MARINE PARKWAY, SUITE 400, REDWOOD CITY, CA
Compare SLNO with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
SLNO
Soleno Therapeutics Inc
|
68.57 | 3.62B | 0 | -38.99M | -24.94M | -2.9966 |
|
VRTX
Vertex Pharmaceuticals Inc
|
395.12 | 99.96B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
589.48 | 60.83B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
454.38 | 59.89B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
660.00 | 40.47B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
313.67 | 37.96B | 3.81B | -644.79M | -669.77M | -6.24 |
Soleno Therapeutics Inc Stock (SLNO) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-23-25 | Initiated | TD Cowen | Buy |
| Mar-05-25 | Resumed | Stifel | Buy |
| Dec-02-24 | Reiterated | Robert W. Baird | Outperform |
| Dec-02-24 | Reiterated | Stifel | Buy |
| Sep-03-24 | Initiated | H.C. Wainwright | Buy |
| May-10-24 | Initiated | Robert W. Baird | Outperform |
| Feb-05-24 | Initiated | Piper Sandler | Overweight |
| Jan-23-24 | Initiated | Stifel | Buy |
| Nov-21-23 | Resumed | Guggenheim | Buy |
| Sep-29-20 | Initiated | Guggenheim | Buy |
| Jan-10-20 | Initiated | Craig Hallum | Buy |
| Dec-23-19 | Initiated | Oppenheimer | Outperform |
| Feb-13-18 | Reiterated | Maxim Group | Buy |
View All
Soleno Therapeutics Inc Stock (SLNO) Latest News
Soleno Therapeutics (SLNO) Drops Amid Critical Scorpion Report -- Hagens Berman - PR Newswire
Wells Fargo initiates Soleno Therapeutics stock with Overweight rating - Investing.com India
Soleno Therapeutics Inc. Hits Price Floor — Bounce IncomingWeekly Stock Analysis & Consistent Profit Trade Alerts - classian.co.kr
Top Analysts Pick: 3 Stocks to Buy Now with Significant Upside - AInvest
Wells Fargo Initiates Soleno Therapeutics at Overweight With $123 Price Target - MarketScreener
INVESTOR ALERT: Investigation of Soleno Therapeutics, Inc. (SLNO) Announced by Holzer & Holzer, LLC - GlobeNewswire
INVESTOR ALERT: Investigation of Soleno Therapeutics, Inc. (SLNO) Announced by Holzer & Holzer, LLC - GlobeNewswire Inc.
Scorpion Capital says remain short Soleno Therapeutics - MarketScreener
Down 21.7% in 4 Weeks, Here's Why Soleno Therapeutics (SLNO) Looks Ripe for a Turnaround - Yahoo Finance
Cantor Fitzgerald reiterates Overweight rating on Soleno Therapeutics stock By Investing.com - Investing.com Australia
Cantor Fitzgerald reiterates Overweight rating on Soleno Therapeutics stock - Investing.com
Baird reiterates Outperform rating on Soleno Therapeutics stock amid short report - Investing.com
Soleno Therapeutics plunges after short report from Scorpion Capital - MSN
Soleno Therapeutics stock maintains Buy rating at TD Cowen on strong sales momentum - Investing.com
H.C. Wainwright raises Soleno Therapeutics stock price target to $110 on VYKAT XR outlook - Investing.com
Soleno Therapeutics price target raised to $110 from $100 at H.C. Wainwright - TipRanks
Strong Buy Recommendation for Soleno Therapeutics: Promising Outlook and Impressive Sales Performance of VYKAT XR - TipRanks
Soleno Therapeutics Engages Investors in Roadshow - TipRanks
Soleno Therapeutics : August 2025 Corporate Presentation - MarketScreener
How is Soleno Therapeutics Inc. managing supply chain issuesMarket Trend Summary & Expert Curated Trade Setups - mustnews.co.kr
Soleno Therapeutics stock dips on proposed $200M offering - MSN
Soleno Therapeutics Plummets 7.41% as Short-Seller Raises Safety Concerns, Stock Ranks 207th in 208.56% Volume Surge - AInvest
Soleno Therapeutics Stock Slumps After Scorpion Capital Reveals Short Position: But Retail’s Not Pessimistic Yet - Stocktwits
Soleno Under Serious Scrutiny As Short Seller Alleges PWS Drug Is Overpriced, Unsafe - Benzinga
Scorpion Capital discloses short position in drugmaker Soleno - whbl.com
Short Covering May Lift Soleno Therapeutics Inc. in Near TermQuarterly Growth Report & AI Powered Trade Plan Recommendations - classian.co.kr
Soleno Therapeutics shares fall 9.41% intraday after Scorpion Capital publishes short report. - AInvest
Soleno Therapeutics Plunges 9.47%—What’s Behind the Selloff? - AInvest
Soleno Therapeutics Plunges 9.68%: Short-Seller Allegations and Technical Breakdowns Spark Bearish Frenzy - AInvest
Soleno Therapeutics stock falls after Scorpion Capital short report By Investing.com - Investing.com India
Soleno Therapeutics stock falls after Scorpion Capital short report - Investing.com
Soleno Therapeutics Plunges 10.81% Amid Investor Sentiment Shift - AInvest
Scorpion Capital shorts drug developer Soleno - MarketScreener
Soleno Therapeutics plunges after short report from Scorpion Capital (SLNO:NASDAQ) - Seeking Alpha
Scorpion Capital says we are short Soleno Therapeutics - MarketScreener
Is Soleno Therapeutics Inc. Starting a New UptrendWeekly Market Outlook & Weekly Top Performers Watchlists - newsyoung.net
What is Soleno Therapeutics Inc.’s market positionChart Signals & Capital Efficient Trade Techniques - sundaytimes.kr
Soleno (SLNO) Q2 Revenue Jumps 30% - AOL.com
What is the long term forecast for Soleno Therapeutics Inc. stockInsider Accumulation Tracker - thegnnews.com
Soleno Therapeutics Inc. Chart Enters High Volatility ZoneAI Driven Buy Alert Trade Blueprint Released - metal.it
Soleno Therapeutics: Analysts Predict 43.2% Upside Potential - AInvest
How Much Upside is Left in Soleno Therapeutics (SLNO)? Wall Street Analysts Think 43.15% - Yahoo Finance
Here's Why Momentum in Soleno Therapeutics (SLNO) Should Keep going - Yahoo Finance
Soleno Therapeutics Provides Update on U.S. Launch of VYKAT(TM) XR and Reports Second Quarter 2025 Financial Results - ADVFN Brasil
Regression Model Predicts Rangebound Movement in Soleno Therapeutics Inc.High Growth Low Risk Stock Selection Gets Analyst Nod - metal.it
Soleno signals $500M cash war chest and robust Vykat XR launch trajectory while advancing EU expansion - MSN
Soleno Therapeutics Posts Strong Q2 Earnings, Expects Continued Growth Despite Challenges. - AInvest
A Quick Look at Today's Ratings for Soleno Therapeutics(SLNO.US), With a Forecast Between $110 to $145 - 富途牛牛
Soleno Therapeutics, Inc. (NASDAQ:SLNO) Q2 2025 Earnings Call Transcript - Insider Monkey
Soleno Therapeutics’ Earnings Call Highlights Success and Optimism - TipRanks
Soleno Therapeutics Receives Bullish Rating from Guggenheim, Price Target Raised to $106.00 - AInvest
Soleno Therapeutics Inc Stock (SLNO) Financials Data
Revenue
Net Income
Cash Flow
EPS
Soleno Therapeutics Inc Stock (SLNO) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Hirano Patricia C | SEE REMARKS |
Jul 01 '25 |
Sale |
82.76 |
3,830 |
316,971 |
13,206 |
0.94%
1.72%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):